O1–06–05: The novel BACE inhibitor MK‐8931 dramatically lowers CSF beta‐amyloid in patients with mild‐to‐moderate Alzheimer's disease-Reference-Cited by-同舟云学术

O1–06–05: The novel BACE inhibitor MK‐8931 dramatically lowers CSF beta‐amyloid in patients with mild‐to‐moderate Alzheimer's disease

Published:2013-07 Issue:4S_Part_3 Volume:9 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Forman Mark¹,Kleijn Huub‐Jan¹,Dockendorf Marissa¹,Palcza John¹,Tseng Jack¹,Canales Christina¹,Egan Michael¹,Kennedy Matthew¹,Laterza Omar¹,Ma Lei¹,Scott Jack¹,Tanen Michael¹,Apter Jeffrey²,Backonja Miroslav³,Ereshefsky Larry⁴,Gevorkyan Hakop⁵,Jhee Stanford⁴,Rynders Rebecca³,Zari Arian⁴,Bryan Ellie⁴,Wagner John¹,Troyer Matthew¹,Stone Julie¹

Affiliation:

1. Merck Whitehouse Station New Jersey United States

2. Princeton Medical Institute Princeton New Jersey United States

3. CRI Lifetree Research Salt Lake City Utah United States

4. Parexel International Early Phase Glendale California United States

5. Parexel International Glendale California United States

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2013.04.083

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small-molecule drugs development for Alzheimer's disease;Frontiers in Aging Neuroscience;2022-11-01

2. What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials;Journal of Neurochemistry;2020-05-09

3. Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease;European Journal of Medicinal Chemistry;2019-12

4. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects;Journal of Alzheimer's Disease;2019-09-17

5. BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines;Frontiers in Aging Neuroscience;2018-07-26